Methods and compositions for treating mammalian nerve tissue injuries
First Claim
1. A method for treating an injury to nerve tissue of a mammalian patient, the method comprising administering an effective amount of a composition comprising at least one polyalkylene glycol selected from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers and mixtures thereof to the patient so that the polyalkylene glycol is delivered via the patient'"'"'s vascular system to the site of the injured nerve tissue, wherein the polyalkylene glycol is at least 30% by weight in the composition.
2 Assignments
0 Petitions
Accused Products
Abstract
To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.
-
Citations
20 Claims
- 1. A method for treating an injury to nerve tissue of a mammalian patient, the method comprising administering an effective amount of a composition comprising at least one polyalkylene glycol selected from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers and mixtures thereof to the patient so that the polyalkylene glycol is delivered via the patient'"'"'s vascular system to the site of the injured nerve tissue, wherein the polyalkylene glycol is at least 30% by weight in the composition.
-
20. A method for treating an injury to nerve tissue of a mammalian patient, the method comprising administering an effective amount of a composition comprising at least one polyalkylene glycol selected from the group consisting of polymethylene glycol, polyethylene glycol, polypropylene glycol, polybutylene glycol, polypentylene glycol, polyhexylene glycol, polyheptylene glycol, polyoctylene glycol, polynonylene glycol, and polydecylene glycol, and branched and structural isomers and mixtures thereof to the patient so that the polyalkylene glycol is delivered via the patient'"'"'s vascular system to the site of the injured nerve tissue, wherein the polyalkylene glycol is about 15% to about 50% by weight in the composition.
Specification